Do you think there would be benefit in using sparsentan over irbesartan for FSGS given a higher percentage of patients with partial remission of proteinuria on sparsentan despite no significant difference in eGFR slope in the DUPLEX Trial?  

I think yes. The between-group difference in proteinuria reduction is compelling and still stands as an important surrogate endpoint in a disease in which effective treatments are lacking. Although the between-group differences in eGFR slope were not significant, there were several factors that may ...

No advantage of sparsentan.